DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348)

UPDATED INFORMATION OF THE GROUP'S PRODUCTS

This announcement is made by Dawnrays Pharmaceutical (Holdings) Limited (the "Company") on a voluntary basis to keep shareholders and potential investors informed of the latest development of the Company and its subsidiaries (collectively referred to as the "Group").

The board of directors of the Company (the "Board") is pleased to announce that "Levocetirizine Dihydrochloride Tablets 5mg", (brand name "Xikexin"「西可新」), an anti-allergic drug of Suzhou Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the Group ("Suzhou Dawnrays"), has been granted approval by National Medical Products Administration for passing the consistency of quality and efficacy evaluation of generic drugs (the "Consistence Evaluation"). Meanwhile, the Board is also pleased to announce that an anti-infective drug of Suzhou Dawnrays, "Cefoperazone Sodium and Tazobactam Sodium for Injection (4:1) 1.0g and 2.0g", has obtained approval for drug registration by the National Medical Products Administration recently.

As a significant reform and regulatory initiative introduced by the State Council and the National Medical Products Administration in the recent years, the Consistence Evaluation fundamentally ensures that all the generic drugs will truly be of the same quality standard and efficacy as their counterparts originally produced by international pharmaceutical companies, solidly safeguarding the treatment quality and thus the health of the public.

**for identification purpose only*

With the effect of selective histamine H1 receptor antagonist, Levocetirizine Dihydrochloride is an anti-allergic drug commonly used clinically for curing allergy-related syndromes of diseases such as seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. Since the drug does not have any apparent anticholinergic or anti-5-hydroxytryptamine effect, its effect on central inhibition is relatively small, making it the favourite medicine for patients with allergic rhinitis and urticaria. The renowned quality of "Xikexin" (西可新), a product of the Group, has been highly recognized by clinical doctors and patients since the product launch in 2006.

Cefoperazone Sodium and Tazobactam Sodium for Injection (4:1) is a an anti-infective compound combination of Cefoperazone Sodium, the third generation of the cephalosporins, and Tazobactam Sodium, a kind of β-Lactamase enzyme inhibitors. Compared to the inhibition efficacy of Sulbactam Sodium, another kind of β-Lactamase inhibitors, that of Tazobactam Sodium is stronger. Therefore, it is clinically used in treatment for moderate and severe infections of β-Lactamase bacteria arising from drug resistance against cefoperazone alone and susceptible to the product.

The newly obtained approval on Consistence Evaluation is not only a further recognition of the Group's long-term commitment of "Quality First" as well as the quality and efficacy of product, but also a momentum for further market expansion accelerating the progress of substituting originally created medicines and thus providing patients with a choice of economical medicines of quality.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 15 July 2019

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; and three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.